Pierre-Yves Bochud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3452845/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology, 2010, 138, 1338-1345.e7.	1.3	1,056
2	Toll-like Receptor 4 Polymorphisms and Aspergillosis in Stem-Cell Transplantation. New England Journal of Medicine, 2008, 359, 1766-1777.	27.0	408
3	Bacteremia due to viridans streptococci in neutropenic patients: A review. American Journal of Medicine, 1994, 97, 256-264.	1.5	285
4	Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology, 2009, 51, 655-666.	3.7	247
5	Cutting Edge: A Toll-Like Receptor 2 Polymorphism That Is Associated with Lepromatous Leprosy Is Unable to Mediate Mycobacterial Signaling. Journal of Immunology, 2003, 170, 3451-3454.	0.8	238
6	Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response Than IL28B Genotype in Patients With Hepatitis C. Gastroenterology, 2011, 140, 1021-1031.e10.	1.3	233
7	IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. Journal of Experimental Medicine, 2013, 210, 1109-1116.	8.5	193
8	Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review. Critical Care Medicine, 2004, 32, S495-S512.	0.9	172
9	Science, medicine, and the future: Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ: British Medical Journal, 2003, 326, 262-266.	2.3	171
10	Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 2012, 143, 1244-1252.e12.	1.3	142
11	Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. Aids, 2007, 21, 441-446.	2.2	139
12	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology, 2012, 55, 384-394.	7.3	138
13	Effect of C-Reactive Protein–Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia. JAMA - Journal of the American Medical Association, 2020, 323, 2160.	7.4	136
14	Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis. Journal of Viral Hepatitis, 2011, 18, 745-759.	2.0	133
15	Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms. PLoS ONE, 2011, 6, e17232.	2.5	131
16	Tollâ€Like Receptor 2 <i>(TLR2)</i> Polymorphisms Are Associated with Reversal Reaction in Leprosy. Journal of Infectious Diseases, 2008, 197, 253-261.	4.0	128
17	Antibiotics in sepsis. Intensive Care Medicine, 2001, 27, S33-S48.	8.2	126
18	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. Journal of Infection, 2018, 76, 20-37.	3.3	125

#	Article	IF	CITATIONS
19	Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nature Communications, 2014, 5, 5699.	12.8	117
20	Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. Journal of Hepatology, 2011, 55, 322-327.	3.7	115
21	IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. PLoS Medicine, 2011, 8, e1001092.	8.4	107
22	Polymorphisms in <i>TLR2</i> Are Associated with Increased Viral Shedding and Lesional Rate in Patients with Genital Herpes Simplex Virus Type 2 Infection. Journal of Infectious Diseases, 2007, 196, 505-509.	4.0	100
23	Viral genotype-specific role of PNPLA3 , PPARG , MTTP, and IL28B in hepatitis C virus-associated steatosis. Journal of Hepatology, 2011, 55, 529-535.	3.7	98
24	IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. Journal of Hepatology, 2011, 55, 980-988.	3.7	97
25	Risk factors for candidemia: a prospective matched case-control study. Critical Care, 2020, 24, 109.	5.8	92
26	<i>PTX3</i> Polymorphisms and Invasive Mold Infections After Solid Organ Transplant: Figure 1 Clinical Infectious Diseases, 2015, 61, 619-622.	5.8	91
27	Combined effect of 25â€ <scp>OH</scp> vitamin D plasma levels and genetic <scp><scp>V</scp></scp> <i>itamin </i> <scp>C/scp>C/scp>R</scp> <i>eceptor</i> (<scp><scp>NR 111</scp></scp>) variants on fibrosis progression rate in <scp>HCV</scp> patients. Liver International. 2012. 32. 635-643.	3.9	89
28	Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut, 2015, 64, 1605-1615.	12.1	85
29	Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index. PLoS Genetics, 2014, 10, e1004508.	3.5	80
30	Innate immunogenetics: a tool for exploring new frontiers of host defence. Lancet Infectious Diseases, The, 2007, 7, 531-542.	9.1	76
31	Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nature Communications, 2014, 5, 4675.	12.8	76
32	Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. Aids, 2009, 23, 2387-2395.	2.2	73
33	Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 504-509.	3.7	73
34	Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics, 2009, 10, 1819-1837.	1.3	64
35	Influence of IFNL3/4 Polymorphisms on the Incidence of Cytomegalovirus Infection After Solid-Organ Transplantation. Journal of Infectious Diseases, 2015, 211, 906-914.	4.0	62
36	A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C. PLoS ONE, 2012, 7, e40159.	2.5	60

#	Article	IF	CITATIONS
37	Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development. PLoS ONE, 2013, 8, e64053.	2.5	59
38	Host – hepatitis C viral interactions: The role of genetics. Journal of Hepatology, 2016, 65, S22-S32.	3.7	57
39	Functional polymorphisms of macrophage migration inhibitory factor as predictors of morbidity and mortality of pneumococcal meningitis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3597-3602.	7.1	55
40	IL1B and DEFB1 Polymorphisms Increase Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation. Journal of Infectious Diseases, 2015, 211, 1646-1657.	4.0	54
41	IL-17 receptor AÂand adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. Journal of Allergy and Clinical Immunology, 2016, 137, 1189-1196.e2.	2.9	54
42	A functional microsatellite of the <i>macrophage migration inhibitory factor</i> gene associated with meningococcal disease. FASEB Journal, 2012, 26, 907-916.	0.5	50
43	Species-Specific Recognition of Aspergillus fumigatus by Toll-like Receptor 1 and Toll-like Receptor 6. Journal of Infectious Diseases, 2012, 205, 944-954.	4.0	48
44	<i>IL28B</i> polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. Journal of Viral Hepatitis, 2013, 20, 59-64.	2.0	39
45	The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. Aids, 2014, 28, 1885-1889.	2.2	37
46	Polymorphisms in the lectin pathway of complement activation influence the incidence ofÂacute rejection and graft outcome after kidneyÂtransplantation. Kidney International, 2016, 89, 927-938.	5.2	37
47	A systematic review and metaâ€analysis of <scp>HCV</scp> clearance. Liver International, 2017, 37, 1431-1445.	3.9	37
48	Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology, 2012, 55, 1038-1047.	7.3	36
49	Host genetics of invasive Aspergillus and Candida infections. Seminars in Immunopathology, 2015, 37, 173-186.	6.1	33
50	The recent breakthroughs in the understanding of host genomics in hepatitis C. European Journal of Clinical Investigation, 2010, 40, 950-959.	3.4	28
51	Invasive Aspergillosis Due to <i>Aspergillus</i> Section <i>Usti</i> : A Multicenter Retrospective Study. Clinical Infectious Diseases, 2021, 72, 1379-1385.	5.8	28
52	Transcriptomic Signature Differences BetweenÂSARS-CoV-2 and Influenza Virus Infected Patients. Frontiers in Immunology, 2021, 12, 666163.	4.8	27
53	LILRB1 polymorphisms influence posttransplant HCMV susceptibility and ligand interactions. Journal of Clinical Investigation, 2018, 128, 1523-1537.	8.2	27
54	Susceptibility to Mycobacterium ulcerans Disease (Buruli ulcer) Is Associated with IFNG and iNOS Gene Polymorphisms. Frontiers in Microbiology, 2017, 8, 1903.	3.5	26

#	Article	IF	CITATIONS
55	Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy. Haematologica, 2018, 103, e527-e530.	3.5	26
56	Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis. Open Forum Infectious Diseases, 2020, 7, ofaa075.	0.9	26
57	A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. Hepatology, 2015, 62, 1375-1387.	7.3	25
58	The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C. Journal of Viral Hepatitis, 2011, 18, 768-778.	2.0	24
59	Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection. Gut, 2017, 66, 1829-1837.	12.1	24
60	Bacillus cereus bacteraemia: comparison between haematologic and nonhaematologic patients. New Microbes and New Infections, 2017, 15, 65-71.	1.6	22
61	The novel <i>ss469415590</i> variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. Alimentary Pharmacology and Therapeutics, 2014, 39, 322-330.	3.7	21
62	Impact of the Beta-Glucan Test on Management of Intensive Care Unit Patients at Risk for Invasive Candidiasis. Journal of Clinical Microbiology, 2020, 58, .	3.9	19
63	<i>IL28B</i> polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5: Table 1. Gut, 2012, 61, 1640-1641.	12.1	18
64	Immunogenetics of invasive aspergillosis. Medical Mycology, 2011, 49, S125-S136.	0.7	17
65	Polymorphisms in Tumor Necrosis Factor-α Increase Susceptibility to Intra-Abdominal Candida Infection in High-Risk Surgical ICU Patients*. Critical Care Medicine, 2014, 42, e304-e308.	0.9	17
66	Herpes simplex encephalitis in adult patients with MASP-2 deficiency. PLoS Pathogens, 2019, 15, e1008168.	4.7	17
67	A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virusâ€coinfected patients. Hepatology, 2016, 64, 1462-1472.	7.3	15
68	Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey. Open Forum Infectious Diseases, 2021, 8, ofab471.	0.9	15
69	Virulent infections caused by alpha-haemolytic streptococci in cancer patients and their management. Current Opinion in Infectious Diseases, 1997, 10, 422-430.	3.1	14
70	Host factors and genetic susceptibility to infections due to intracellular bacteria and fastidious organisms. Clinical Microbiology and Infection, 2014, 20, 1246-1253.	6.0	13
71	Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. Journal of Infection, 2018, 76, 489-495.	3.3	13
72	Host response to fungal infections – how immunology and host genetics could help to identify and treat patients at risk. Swiss Medical Weekly, 2016, 146, w14350.	1.6	13

#	Article	IF	CITATIONS
73	Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. PLoS ONE, 2013, 8, e56991.	2.5	12
74	Acute Schistosomiasis: A Risk Underestimated by Travelers and a Diagnosis Frequently Missed by General Practitioners—A Cluster Analysis of 42 Travelers. Journal of Travel Medicine, 2015, 22, 168-173.	3.0	12
75	Risk stratification and immunogenetic risk for infections following stem cell transplantation. Virulence, 2016, 7, 917-929.	4.4	12
76	Cytokines in septic shock. Current Clinical Topics in Infectious Diseases, 2002, 22, 1-23.	0.3	12
77	Evaluation of Mass Spectrometry-Based Detection of Panfungal Serum Disaccharide for Diagnosis of Invasive Fungal Infections: Results from a Collaborative Study Involving Six European Clinical Centers. Journal of Clinical Microbiology, 2019, 57, .	3.9	11
78	Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital. Mycoses, 2021, 64, 1512-1520.	4.0	11
79	High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies. Clinical Infectious Diseases, 2022, 75, 330-333.	5.8	11
80	Cohort profile: The Swiss Transplant Cohort Study (STCS): A nationwide longitudinal cohort study of all solid organ recipients in Switzerland. BMJ Open, 2021, 11, e051176.	1.9	10
81	The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1–infected patients treated with Pegâ€IFNâ€alfaâ€2a and ribavirin. Journal of Viral Hepatitis, 2012, 19, 488-496.	2.0	9
82	IL-4 polymorphism influences susceptibility to Pneumocystis jirovecii pneumonia in HIV-positive patients. Aids, 2019, 33, 1719-1727.	2.2	9
83	Genetic and clinic predictors of new onset diabetes mellitus after transplantation. Pharmacogenomics Journal, 2019, 19, 53-64.	2.0	9
84	Postmortem Cardiopulmonary Pathology in Patients with COVID-19 Infection: Single-Center Report of 12 Autopsies from Lausanne, Switzerland. Diagnostics, 2021, 11, 1357.	2.6	9
85	Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19. Viruses, 2022, 14, 1089.	3.3	9
86	PIRATE project: point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia. BMJ Open, 2017, 7, e017996.	1.9	8
87	Clinical Significance of the CCR5delta32 Allele in Hepatitis C. PLoS ONE, 2014, 9, e106424.	2.5	7
88	Role of biâ€weekly serum galactomannan screening for the diagnosis of invasive aspergillosis in haematological cancer patients. Mycoses, 2018, 61, 350-354.	4.0	7
89	Weighted Genetic Risk Scores and Prediction of Weight Gain in Solid Organ Transplant Populations. PLoS ONE, 2016, 11, e0164443.	2.5	7
90	<i>BRIP1</i> coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease. Oncotarget, 2017, 8, 62842-62857.	1.8	7

#	Article	IF	CITATIONS
91	A New Step toward Individualized Antifungal Prevention in Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 2009, 49, 733-735.	5.8	6
92	The Swiss Transplant Cohort Study: Lessons from the First 6ÂYears. Current Infectious Disease Reports, 2015, 17, 486.	3.0	6
93	Association of lectin pathway proteins with intra-abdominal Candida infection in high-risk surgical intensive-care unit patients. A prospective cohort study within the fungal infection network of Switzerland. Journal of Infection, 2016, 72, 377-385.	3.3	6
94	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. Aids, 2018, 32, 2759-2765.	2.2	6
95	Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing. Frontiers in Genetics, 2019, 10, 1024.	2.3	6
96	Intrahepatic <scp>mRNA</scp> levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C. Liver International, 2013, 33, 94-103.	3.9	5
97	Human microRNA responses predict cytomegalovirus replication following solid organ transplantation. Journal of Infectious Diseases, 2016, 215, jiw596.	4.0	5
98	Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia. Intensive Care Medicine, 2017, 43, 935-939.	8.2	5
99	Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. American Journal of Transplantation, 2019, 19, 238-246.	4.7	5
100	Invasive Hormographiella aspergillata infection in patients with acute myeloid leukemia: Report of two cases successfully treated and review of the literature. Medical Mycology Case Reports, 2021, 32, 68-72.	1.3	5
101	The EHA Research Roadmap: Infections in Hematology. HemaSphere, 2021, 5, e662.	2.7	5
102	Impact of a Nurse Vaccination Program on Hepatitis B Immunity in a Swiss HIV Clinic. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 472-474.	2.1	4
103	A significant effect of the killer cell immunoglobulinâ€like receptor ligand human leucocyte antigenâ€C on fibrosis progression in chronic C hepatitis with or without liver transplantation. Liver International, 2016, 36, 1331-1339.	3.9	4
104	Polymorphisms of SOCS-1 Are Associated With a Rapid HIV Progression Rate. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 189-195.	2.1	4
105	High prevalence of peribronchial focal lesions of airway invasive aspergillosis in hematological cancer patients with prolonged neutropenia. British Journal of Radiology, 2020, 93, 20190693.	2.2	3
106	rs34567942 a Novel Susceptibility Single Nucleotide Polymorphism for Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients. Acta Dermato-Venereologica, 2019, 99, 1303-1304.	1.3	3
107	Frequency and causes of antifungal treatment changes in allogeneic haematopoÃ ⁻ etic cell transplant recipients with invasive mould infections. Mycoses, 2022, 65, 199-210.	4.0	2
100	75 Cutching 2014 70 45 40		

108 75. Cytokine, 2014, 70, 45-46.

3.2 1

#	Article	IF	CITATIONS
109	Reply to Cunha et al. Clinical Infectious Diseases, 2015, 61, 1894-1895.	5.8	0
110	Genetic Determinants of Host Susceptibility to Fungal Diseases in Solid Organ Transplantation and Hematological Patients. , 2017, , 135-151.		0